During the past decade, Dana Farber Community Cancer Care-Quincy conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 11 clinical trials were completed, i.e. on average, 40.7% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 8 clinical trials were completed. i.e. 61.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana Farber Community Cancer Care-Quincy" #1 sponsor was "Dana-Farber Cancer Institute" with 19 trials, followed by "National Cancer Institute (NCI)" with 9 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "SWOG Cancer Research Network" with 2 trials sponsored and "Alliance Foundation Trials, LLC." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana Farber Community Cancer Care-Quincy" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 25 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Dana Farber Community Cancer Care-Quincy" are "Breast Cancer" (14 trials), "HER2-positive Breast Cancer" (3 trials), "Prostate Cancer" (3 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials) and "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7" (3 trials). Many other conditions were trialed in "Dana Farber Community Cancer Care-Quincy" in a lesser frequency.

Most popular intervention types in "Dana Farber Community Cancer Care-Quincy" are "Drug" (32 trials), "Other" (15 trials), "Biological" (6 trials), "Radiation" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (10 trials), "Paclitaxel" (9 trials), "Carboplatin" (4 trials), "Cisplatin" (4 trials) and "Pembrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber Community Cancer Care-Quincy" are 27 trials for "All" genders, 9 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Dana Farber Community Cancer Care-Quincy". undefined are not yet recruiting, 11 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Dana Farber Community Cancer Care-Quincy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber Community Cancer Care-Quincy, 3 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".